Patents by Inventor Appan Srinivas Kandadai

Appan Srinivas Kandadai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11939302
    Abstract: The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: March 26, 2024
    Assignee: The Governors of the University of Alberta
    Inventors: James A. Nieman, Jack Jhamandas, Bing Bai, Alexandr Belovodskiy, Wen Fu, Mostofa Hena, Michael Houghton, Appan Srinivas Kandadai, Ryoichi Kimura, Kamlesh Kumar Sahu, D. Lorne Tyrrell
  • Publication number: 20230399296
    Abstract: The present disclosure provides compounds with increased metabolic stability for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of the present disclosure also include methods of treating the virus infection in a subject with compounds with increased metabolic stability.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 14, 2023
    Inventors: James A. Nieman, M. Joanne Lemieux, Elena Arutyunova, Michael A. Joyce, D. Lorne Tyrrell, Holly Saffran, Bing Bai, Mostofa Hena, Appan Srinivas Kandadai
  • Publication number: 20230136702
    Abstract: Provided herein are compounds, compositions and methods for inhibition of herpesviruses. In some cases, the subject compounds inhibit a herpesvirus in a cell. Also provided are compounds, compositions and methods for treating a herpesvirus in an individual. In some cases, the methods include administering to an individual a therapeutically effective amount of a subject compound to treat the individual for the herpesvirus. In certain embodiments, the compounds disclosed herein are cytomegalovirus (CMV) inhibitors. In certain embodiments, the compounds disclosed herein are human cytomegalovirus (CMV) inhibitors.
    Type: Application
    Filed: March 2, 2021
    Publication date: May 4, 2023
    Inventors: James Nieman, Mostofa Hena, Bing Bai, Appan Srinivas Kandadai, Alexandr Belovodskiy
  • Publication number: 20230108588
    Abstract: The present disclosure provides compounds and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection. Aspects of the present disclosure also include methods of treating a Baltimore Group IV RNA virus infection in a subject. The present disclosure also provides pharmaceutical compositions related to the same.
    Type: Application
    Filed: September 22, 2022
    Publication date: April 6, 2023
    Inventors: James A. Nieman, M. Joanne Lemieux, D. Lorne Tyrrell, Mostofa Hena, Appan Srinivas Kandadai, Alexandr Belovodskiy, Michael A. Joyce, Elena Arutyunova
  • Publication number: 20220226335
    Abstract: The present disclosure provides non-peptidic heterocycle-containing amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.
    Type: Application
    Filed: April 23, 2020
    Publication date: July 21, 2022
    Inventors: Jack Jhamandas, Wen Fu, Ryoichi Kimura, D. Lorne Tyrrell, Ana Clementin, Kamlesh Sahu, Alexandr Belovodskiy, Mostofa Hena, Bing Bai, Appan Srinivas Kandadai, James A. Nieman, Michael Houghton
  • Publication number: 20220204476
    Abstract: The present disclosure provides compounds and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection, such as rhinovirus, coxsackievirus, norovirus and coronavirus. Aspects of the present disclosure also include methods of treating a virus infection in a subject.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 30, 2022
    Inventors: James A. Nieman, M. Joanne Lemieux, D. Lorne Tyrrell, Bing Bai, Alexandr Belovodskiy, Mostofa Hena, Appan Srinivas Kandadai, Michael A. Joyce
  • Publication number: 20220119356
    Abstract: The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.
    Type: Application
    Filed: October 19, 2021
    Publication date: April 21, 2022
    Inventors: James A. Nieman, Jack Jhamandas, Bing Bai, Alexandr Belovodskiy, Wen Fu, Mostofa Hena, Michael Houghton, Appan Srinivas Kandadai, Ryoichi Kimura, Kamlesh Kumar Sahu, D. Lorne Tyrrell